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To investigate the feasibility and safety of a 24-week exercise intervention, compared to
control, in males with Barrett’s oesophagus, and to estimate the effect of the intervention,
compared to control, on risk factors associated with oesophageal
adenocarcinoma development.
Methods
A randomized controlled trial of an exercise intervention (60 minutes moderate-intensity
aerobic and resistance exercise five days/week over 24 weeks; one supervised and four un-
supervised sessions) versus attention control (45 minutes stretching five days/week over
24 weeks; one supervised and four unsupervised sessions) in inactive, overweight/obese
(25.0–34.9 kg/m2) males with Barrett’s oesophagus, aged 18–70 years. Primary outcomes
were obesity-associated hormones relevant to oesophageal adenocarcinoma risk (circulat-
ing concentrations of leptin, adiponectin, interleukin-6, tumour necrosis factor-alpha, C-
reactive protein, and insulin resistance [HOMA]). Secondary outcomes included waist cir-
cumference, body composition, fitness, strength and gastro-oesophageal reflux symptoms.
Outcomes were measured at baseline and 24-weeks. Intervention effects were analysed
using generalised linear models, adjusting for baseline value.
Results
Recruitment was difficult in this population with a total of 33 participants recruited (target
sample size: n = 80); 97% retention at 24-weeks. Adherence to the exercise protocol was
moderate. No serious adverse events were reported. A statistically significant intervention
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effect (exercise minus control) was observed for waist circumference (-4.5 [95% CI -7.5, -1.4]
cm; p< 0.01). Effects on primary outcomes were not statistically significant.
Conclusion
This small, exploratory trial provides important information to inform future trial development
including recruitment rates and estimates of effect sizes on outcomes related to oesopha-
geal adenocarcinoma risk. Future trials should investigate a combined dietary and exercise
intervention to achieve greater weight loss in this population and relax inclusion criteria to
maximize recruitment.
Trial Registration
Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12609000401257
Introduction
During the past three decades, the incidence of oesophageal adenocarcinoma has risen by over
300% in females and 500% in males in Western countries [1–5]. The incidence of the precursor
lesion, Barrett’s oesophagus is also rising rapidly [6,7]. People diagnosed with Barrett’s oesoph-
agus have an oesophageal adenocarcinoma risk of approximately 30–40 times higher than that
of a healthy population [8,9]. Males are particularly at risk of oesophageal adenocarcinoma,
with a male to female ratio of at least 5:1 [1]. If Barrett’s oesophagus does progress to adenocar-
cinoma, prognosis is poor with a 5-year survival rate of 10–15%, despite surgery and chemo-
therapy [10,11]. At present there is limited evidence regarding lifestyle interventions aimed at
reducing cancer risk in males with Barrett’s oesophagus [12].
Lifestyle based interventions such as physical activity have the potential to reduce the risk of
oesophageal adenocarcinoma given that risk factors include overall adiposity [13–17], and in
particular visceral obesity [18–21]. To date, studies on the association between physical activity
and oesophageal adenocarcinoma incidence have been limited, with two prospective cohort
studies showing that increased levels of physical activity were associated with reduced cancer
risk, partly mediated through effects on body weight [22,23]. Notably, a recent study found
that increased levels of the adipocyte-produced hormone leptin, that is typically elevated in
obesity, and insulin resistance were associated with increased risk of oesophageal adenocarci-
noma in men with Barrett’s oesophagus, independent of body mass index (BMI) and other
known confounders [24].
Evidence from exercise trials in men and women at risk of either breast or colon cancer sug-
gests that physical activity, at levels recommended for cancer prevention, can reduce adiposity,
leptin, some inflammatory markers and insulin resistance [25–27]. Whether or not exercise
can improve adiposity and obesity-associated hormones in males with Barrett’s oesophagus is
unknown. Hence, current guidelines for the management of Barrett’s oesophagus do not pro-
vide any recommendations around lifestyle changes or weight loss [28,29]; most likely due to
the lack of evidence on any beneficial or harmful effects.
The ‘Exercise and the Prevention of Oesophageal Cancer’ (EPOC) study aimed to investi-
gate the effect of an exercise program versus stretching on risk factors associated with oesopha-
geal adenocarcinoma development in overweight or obese, inactive males with Barrett’s
oesophagus. The detailed trial protocol has been previously described [30]. It was hypothesized
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that serum concentrations of leptin, adiponectin (total and high molecular weight),
interleukin-6 [IL-6], tumour necrosis factor-alpha [TNF-α], C-reactive protein [CRP], and in-
sulin resistance [HOMA] would differ between participants randomized to the exercise group
and the control group. The trial was designed to be powered to detect effects for these primary
outcomes. Here we report on feasibility (recruitment rates, retention and intervention adher-
ence), adverse events and provide an estimate of effect sizes on primary and secondary out-
comes (waist circumference, body composition, fitness, strength and gastro-oesophageal reflux
symptoms) to inform future trial development.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist are available as supporting in-
formation; see S1 CONSORT Checklist and S1 Protocol. EPOC was a two-arm, randomized
controlled trial in males with Barrett’s oesophagus, conducted in Brisbane, Australia. Partici-
pants were recruited between May 2009 and September 2010, with data collected between May
2009 and March 2011. The trial was registered with the Australian New Zealand Clinical Trials
Registry in June 2009 (ACTRN12609000401257; http://www.anzctr.org.au/). Due to the tight
study timeline, participant recruitment opened prior to trial registration such that one partici-
pant had been recruited prior to the trial registration approval. There are no ongoing or
related trials.
Ethics Statement
The trial was approved by The University of Queensland Medical Research Ethics Committee
(October 2008), Royal Brisbane and Women’s Hospital Human Research Ethics Committee
(October 2008), UnitingCare Health Human Research Ethics Committee (April 2009), Prin-
cess Alexandra Hospital Human Research Ethics Committee (July 2009) and The Prince
Charles Hospital Human Research Ethics Committee (December 2009). All participants pro-
vided written, signed informed consent.
Participant Recruitment
Multiple strategies were used to recruit participants. Patients were primarily recruited through
gastroenterology departments (three large tertiary hospitals, one private hospital and a private
clinic) in Brisbane, Australia. Patients were provided with an information sheet by their treat-
ing doctor during routine appointments and given an expression of interest form to complete
and post, or were identified from four hospital databases by nursing staff and mailed the infor-
mation sheet and expression of interest form (n = 303). In addition, study information was
mailed to Barrett’s oesophagus patients who had given permission to be included on a research
study database (n = 100). Patients who returned the expression of interest form were contacted
by study personnel via telephone to explain the study in further detail, screen for eligibility and
answer any questions. Eligibility criteria included: Barrett’s oesophagus (defined as the abnor-
mal appearance of the lining of the distal oesophagus on endoscopy, in addition to histological
evidence of intestinal metaplasia on biopsy) [31]; male; age 18–70 years; and living in greater
Brisbane, Australia (population 2 million). Exclusion criteria included: non-English speaking;
body mass index (BMI)< 25.0 kg/m2 or> 34.9 kg/m2; performing> 60 min/week of moder-
ate-vigorous intensity exercise during the previous 6-weeks; weight loss or gain 5kg during
the past 6-months; and major co-morbidities (such as cardiac, respiratory, renal, liver, neuro-
logical or inflammatory disease). Patients with a BMI 35 kg/m2 were excluded due to in-
creased risks of adverse events. Weight stability within ±5kg was included to ensure that the
metabolic and inflammatory biomarkers of interest had been relatively stable prior to study
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commencement. Eligible participants who consented to study participation provided signed,
written consent prior to baseline assessment. Following baseline data collection, participants
were randomised to the exercise group or the control group. The randomization sequence was
generated by a research assistant not involved in the study, using a computer-generated ran-
dom number table (http://www.randomization.com), with block randomisation. Group alloca-
tion was concealed from the investigators using sealed, numbered envelopes. It is not possible
to blind participants to the group allocation in exercise trials. However, all data were collected
by research assistants blinded to group allocation and all primary outcomes were objectively
measured, with laboratory staff blinded to study group.
Exercise Intervention
The program consisted of 60 minute exercise sessions, five days/week for 24 weeks. Each ses-
sion comprised 30 minutes of moderate-intensity (60–70% age predicted maximum heart rate)
aerobic exercise and 30 minutes of resistance exercise (1–2 sets of 8–15 repetitions on major
muscle groups) plus a 5-minute warm-up and cool-down. One session per week was performed
at a hospital gymnasium in small groups under the supervision of study personnel (physiother-
apist/exercise physiologist), the remaining four sessions were performed independently at a
private health club (free health club memberships were provided). Participants performed aer-
obic exercise on treadmills, cycling or rowing stationary ergometers and elliptical machines.
Exercise intensity was determined using the unmodified BORG scale [32]. Participants main-
tained their rate of perceived exertion between “somewhat hard” and “hard” [32]. Resistance
exercises included: chest press, leg press, shoulder press, seated row, lunges, assisted chin up,
assisted dip and core stability. Resistance was set at achieving muscular fatigue between 12–15
repetitions initially and then 8–10 repetitions after eight weeks of training. Resistance, therefore
progressively increased as the subjects enhanced their strength. After 8 weeks, participants in-
creased the number of sets completed from one to two. Adherence was monitored through
daily participant-completed exercise diaries and attendance at the private health clubs was
recorded electronically.
Attention Control
Participants allocated to the control group attended a hospital gymnasium once a week to per-
form 45 minutes of stretching in small groups under the supervision of study personnel. They
were also instructed to perform the stretching program independently at home, four days/week
and not to commence a new exercise program during the study period. At the conclusion of
the study participants in the control group were offered an exercise program and a complimen-
tary three month membership to a private health club. Both exercise and control participants
were instructed to not change their usual diet and to continue their regular anti-reflux medica-
tion regime for the duration of the trial.
Data Collection
Demographic characteristics and medical history were obtained from an interviewer-adminis-
tered questionnaire at baseline. All other measures were taken by trained blinded assessors at
baseline, 12-weeks and 24-weeks except for medication use (documented daily), smoking hab-
its (recorded every 4 weeks) and adverse events (documented in exercise diary). Participants re-
corded any adverse events (bodily complaint, injury or illness) in their daily exercise diaries
regardless of the cause of the complaint. Exercise diaries were collected at the end of the study
and any recorded adverse events were coded.
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Physical activity was assessed using the International Physical Activity Questionnaire
(IPAQ), (long form, last 7 days, self-administered format) [33,34]. Total energy intake was as-
sessed using a validated, self-administered, 170-item food frequency questionnaire [35]. Body
fat mass and lean mass were determined in triplicate by bioimpedance spectroscopy (Impe-
diMed SFB7, ImpediMed Ltd., Australia). Typical coefficients of variation within a measure-
ment session range from 0.3 to 3.0% [36]. Waist circumference was measured in duplicate at
the midpoint between the lower costal (rib) border and the iliac crest. Peak oxygen uptake
(VO2peak) was quantified using a Cortex Metamax 3 portable metabolic analyser (Cortex: bio-
physik, GMbH, Germany) while participants performed the Modified Shuttle Walk Test [37].
One-repetition maximum (1RM) bench press and leg press tests measured muscle strength.
Gastro-oesophageal reflux symptoms were measured using the Gastro-oesophageal Reflux Dis-
ease Impact Scale [38]. Fasting blood samples of 30 ml were collected by pathology personnel
between 08:00–10:00am, at least 24 hours post exercise. Blood samples were centrifuged within
20 minutes of collection and stored at -80°C until assay.
Blood Analysis
Serum leptin was analysed via radioimmunoassay (RIA) (Linco Research, Missouri, USA). The
inter- and intra- coefficients of variation (CV) were< 8%. Serum adiponectin (total and
HMW) was determined by an enzyme-linked immunosorbent assay (ELISA) (Alpco Diagnos-
tics, Salem, USA). The inter- and intra-assay (CV) were< 8%. Serum concentrations of IL-6
and TNF-α were measured using a Milliplex suspension array system (Millipore, Billerica,
USA), with inter-assay CV of< 8% and intra-assay CV of< 6%. Serum concentrations of CRP
were analysed using a high sensitivity Particle Enhanced Immunonephelometry assay (Siemens
Healthcare Diagnostics Products GmbH, Marburg, Germany). Inter- and intra-assay CV were
 5%. Fasting serum insulin was analysed using an immunoenzymatic ‘sandwich’ assay via an
ACCESS system (Beckman Coulter, Fullerton, USA) and plasma glucose concentrations deter-
mined with an oxygen rate method via the SYNCHRON system (Beckman Coulter, Fullerton,
USA) with an inter- and intra-assay CV of< 5% for both insulin and glucose. Insulin resis-
tance was calculated using the homeostasis model assessment (HOMA) formula (fasting insu-
lin x fasting glucose/22.5) [39]. No biomarker values were under the laboratory’s detection
limits. Participants were provided with a report of their blood results at the end of the study
and were instructed to follow up any abnormal results with their doctor.
Statistical Analysis
All data were entered into PASW statistical software (Version 18; SPSS inc., Chicago, IL). The
analysis assessed the intervention effect (intervention—control) based on intention-to-treat
principles. The amount of missing data was minimal at each assessment (n = 0 for blood, adi-
posity and GORD outcomes; n = 4 for fitness outcomes due to fault with measurement equip-
ment; and n = 5 for strength outcomes due to musculoskeletal injury). In addition, two
participants in the exercise group recorded extreme values for insulin and IL-6 at all assess-
ments. Due to the small sample size, a decision was made post-hoc to exclude the data for all
blood outcomes from these two participants to avoid undue influence for these
outlying observations.
The mean changes in outcomes from baseline to week-24 were computed (mean changes at
week-12 were included as supplementary analysis). Residuals of models for all outcomes, with
the exception of IL-6 approximated a normal distribution. A univariate analysis of covariance
(ANCOVA) assessed whether changes differed between the two groups at each follow-up as-
sessment. Models were adjusted for baseline values of the outcome variable to account for any
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differences between groups at baseline and regression to the mean. Statistical tests were two-
sided and p< 0.05 was considered statistically significant (as per trial protocol and sample size
estimation). To account for testing multiple primary outcomes, p< 0.007 was considered
statistically significant.
The study tested the null hypothesis that the mean difference between groups is zero and
the alternative hypothesis that the mean difference is greater than zero. Between-group differ-
ences for mean changes in primary outcomes, that were greater than or equal to 10% (defined
a priori), were considered noteworthy.
Sample Size
We estimated a sample size of 40 participants per group (80 in total) was required to detect a
minimum difference of 10% in primary outcomes between the exercise and control group, as-
suming 80% power, a type І error of 5% and allowing for 10% attrition (two-tailed) [30]. The
10% difference in means between groups and standard deviations for each of the outcomes
were estimated from published data on each of the biomarkers in previous clinical trials in
obese, inactive healthy males [40–47].
Results
Recruitment and Retention
Of the 403 patients mailed study information, 113 (28.0%) expression of interest forms were re-
ceived. Only seven expressions of interest forms were returned from patients who were provid-
ed the study information by their gastroenterologists during a routine consultation. Thus, a
total of 120 men expressed interest in the study over the 17-month recruitment period (Fig. 1).
Of these men, 20 (16.7%) did not meet the inclusion criteria (living outside study area [n = 11];
aged>70 years [n = 5]; not diagnosed with Barrett’s Oesophagus [n = 4]) and a further 51
(42.5%) were excluded. Reasons for exclusion included: participating in more than one hour/
week exercise (n = 18); co-morbidity (n = 17); BMI<25.0 kg/m2 (n = 14); BMI>35.0 kg/m2
(n = 1); and>5kg weight loss in previous six months (n = 1). Of those eligible (n = 49), 16
(32.7%) men declined to participate (lack of time [n = 14]; no longer interested [n = 2]). A total
of 33 participants provided informed consent and were randomly allocated to the exercise
(n = 17) or control group (n = 16). Participants were primarily white, aged (mean ± SD) 57.4 ±
8.9 years and obese (30.1 ± 2.9 kg/m2). The majority of participants were taking anti-reflux
medication (94%) and were classified as having ‘fairly well controlled’ reflux symptoms (55%),
based on Gastro-oesophageal Reflux Disease Impact Scale scores. The two groups were similar
in demographic characteristics, body composition, smoking, anti-reflux medication use, and
reflux symptom control at baseline (Table 1). Despite randomization, mean baseline concen-
trations of leptin, adiponectin (total and HMW), and HOMA scores differed between the exer-
cise and control groups by more than 10% (Table 2). Retention in the trial was excellent
(97.0%) with only one participant withdrawing from the control group for personal reasons.
Adherence
Based on all exercise (supervised and unsupervised) recorded in the daily exercise diaries over
the 24-week study period, participants in the exercise group recorded a median of 3.5 hours of
exercise per week (25th, 75th percentiles: 3.1, 5.3 hrs/week). Exercise group participants at-
tended 78% of their supervised sessions and 56% of their independent gym-based sessions
based on daily exercise diaries (53% attendance based on electronic records) and recorded a
median of 0.5 hours (0.1, 1.3 hours) of non-protocol exercise per week (e.g. mountain biking,
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swimming). Control group participants recorded a median of 0.2 hours: 0.0, 0.9 hours) of non-
protocol exercise per week on their daily exercise diaries and attended 56% of their supervised
stretching sessions. Although control group participants were advised to not change their usual
physical activity levels, five participants (31%) recorded greater than one hour of exercise per
week on at least 5 weeks over the study period. Compared to control group participants, partic-
ipants in the exercise groups self-reported significantly more leisure-time physical activity, but
no difference in occupational and household physical activity levels and sitting time (S1 Table).
There was a significant difference in change in total energy intake between groups from base-
line to 24-weeks (p = 0.04; S1 Table).
Fig 1. Participant flow diagram.
doi:10.1371/journal.pone.0117922.g001
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Adverse Events
Adverse events attributable to the study included minor musculoskeletal complaints (n = 4),
which was similar between the exercise (n = 2) and control (n = 2) groups. No severe adverse
events were reported. Mild muscle stiffness/soreness was reported by 11 (64.7%)
intervention participants.
Primary Outcomes
Changes in primary outcomes from baseline to 24-weeks are shown in Table 2 (changes from
baseline to 12-weeks are shown in S2 Table; medians [25th, 75th percentiles] at baseline, 12-
weeks and 24-weeks are shown in S3 Table). There were no statistically significant between-
group differences for changes in any of the obesity-associated hormones measured (Table 2).
Table 1. Baseline characteristics of participants allocated to the exercise and control groups.
Exercise Group Control Group
n 17 16
Age (years) 57.2 ±7.5 57.6 ± 10.4
Body weight (kg) 94.7 ±10.5 92.4 ± 9.6
BMI (kg/m2) 30.8 ±2.6 29.4 ± 3.1
Peak oxygen consumption (ml/kg/min) 25.8 ± 8.2 26.8 ± 7.5
Moderate-to-vigorous exercise (min/week)a 0 (0, 43) 0 (0, 38)
Sitting time (h/wk)a 56 (35, 63) 41 (29, 52)
Total calories (kcal/day) 2252 ± 592 2176 ± 585
Smoking history
Current smoker 1 (5.9) 1 (6.3)
Ex-smoker 8 (47.1) 5 (31.3)
Never-smoker 8 (47.1) 10 (62.5)
Anti-reﬂux medication
Proton-pump inhibitor 15 (88.2) 14 (87.5)
H2-receptor antagonist 0 (0) 1 (6.3)
Over the counter 1 (5.9) 2 (12.5)
Nil 1 (5.9) 1 (6.3)
Gastro-oesophageal reﬂux symptomsb
Very well controlled 2 (11.8) 5 (31.3)
Fairly well controlled 11 (64.7) 7 (43.8)
Uncontrolled 3 (17.6) 2 (12.5)
Poorly controlled 1 (5.9) 2 (12.5)
Highest level of education
High school certiﬁcate 5 (29.4) 5 (31.3)
Technical college certiﬁcate 4 (23.5) 4 (25.0)
University degree 8 (47.1) 7 (43.8)
Employment
Full-time 13 (76.5) 9 (56.3)
Part-time 0 (0) 3 (18.8)
Retired 4 (23.5) 4 (25.0)
Data are mean ± SD, median (25th, 75th percentile) or n (%).
a measured using International Physical Activity Questionnaire (recreational physical activity).
b measured using Gastro-oesophageal reﬂux disease impact scale.
doi:10.1371/journal.pone.0117922.t001
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Secondary Outcomes
There were no statistically significant between-group differences in body weight and body
composition at 24-weeks (Table 3), although a statistically significant intervention effect on
waist circumference was observed (-4.5 [95% CI-7.5, -1.4] cm; p< 0.01). There was no signifi-
cant difference in gastro-oesophageal reflux symptoms between groups at 24-weeks. Compared
to control group participants, participants in the exercise groups observed greater improve-
ments in cardiovascular fitness and upper-body strength but not lower-body strength. Changes
from baseline to 12-weeks are shown in S4 Table.
Discussion
This is the first trial to attempt an exercise intervention in men with Barrett’s oesophagus and
provides useful pilot data to inform effect size estimation in future larger-scale trials. Overall,
recruitment was difficult in this population and the target sample size of 80 participants was
not achieved. Although no statistically significant between-group differences were observed for
any of the primary outcomes there was some evidence to suggest that exercise may have poten-
tially meaningful effect on leptin.
Table 2. Obesity-related hormone outcomes at baseline and week-24 comparing participants in the exercise group (n = 15) and control group
(n = 15).




Mean (SD) Mean (SD) Mean (95%CI) % change Mean (95% CI) p-value a
Leptin (ng/mL)
Exercise group 11.7 (7.7) 9. 4 (6.5) -2.4 (-5.0, 0.08) -20.5 -3.0 (-6.6, 0.6) 0.09
Control group 13.0 (9.2) 13.6 (10.7) 0.6 (-1.9, 3.1) 4.6
Total adiponectin (μg/mL)
Exercise group 6.5 (2.7) 5.1 (1.8) -1.3 (-1.8, -0.7) -16.9 0.26 (-0.5, 1.0) 0.48
Control group 5.9 (2.8) 4.5 (1.5) -1.6 (-2.3, -0.8) -27.8
HMW adiponectin (μg/mL)
Exercise group 2.8 (1.5) 2.0 (1.8) -0.6 (-1.0, 0.2) -17.8 -0.06 (-0.6, 0.5) 0.83
Control group 2.1 (1.4) 1.7 (1.0) -0.5 (-1.0, 0.1) -23.8
IL-6 (pg/mL)
Exercise group 4.3 (3.4) 4.5 (4.7) - - 0.93 (0.56, 1.55)b 0.77
Control group 4.3 (5.2) 4.5 (4.5) - -
TNF-α (pg/mL)
Exercise group 7.0 (2.8) 7.3 (3.5) 0.3 (-1.1, 1.7) 4.3 0.34 (-1.7, 2.3) 0.73
Control group 6.5 (1.9) 6.5 (3.1) -0.01 (-1.4, 1.4) -0.2
CRP (mg/L)
Exercise group 3.5 (6.3) 1.9 (1.7) -1.6 (-2.4, -0.7) -45.7 0.61 (-0.6, 1.8) 0.32
Control group 3.5 (5.1) 1.3 (1.5) -2.1 (-2.9, -1.2) -60.0
HOMA
Exercise group 2.6 (1.1) 2.2 (1.1) -0.47 (-0.9, 0.0) -18.2 -0.05 (-0.7, 0.6) 0.88
Control group 3.6 (2.3) 3.2 (2.5) -0.43 (-0.9, 0.0) -11.9
HMW, high molecular weight; IL-6, interleukin-6; TNF-α, tumour necrosis factor-alpha; CRP, C-reactive protein; HOMA, homeostasis model assessment.
a Change in exercise group versus change in control group, adjusted for baseline value (ANCOVA).
b Backtransformed from natural log; expressed as relative ratio.
doi:10.1371/journal.pone.0117922.t002
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Despite recruitment via a number of sources, the relatively low prevalence of Barrett’s oe-
sophagus in the population (variously estimated at approximately 1–2%) [6,7] and the strict el-
igibility criteria employed in this study meant that we did not reach our sample size target. The
study was therefore underpowered to detect differences in all of the outcomes associated with
oesophageal cancer risk (for example, the sample provided less than 70% power to detect the
difference observed in leptin concentrations and total body weight and less than 30% power to
detect the difference observed in fat mass). Consequently findings of this trial must be consid-
ered exploratory but provide useful pilot data to estimate effect sizes for future trials.
Due to the lack of evidence on exercise intervention in Barrett’s oesophagus patients, this
pilot study was designed as an efficacy trial (versus an effectiveness trial) and aimed to recruit a
relatively homogenous sample of Barrett’s oesophagus patients with a strict intervention proto-
col including attendance at supervised exercise sessions [48]. Approximately half of the men,
who expressed interest in the study and met inclusion criteria, were excluded due to the strict
eligibility criteria. In addition, almost a third of eligible patients declined to participate in the
study, primarily due to lack of time. Low levels of recruitment and participation may be a
Table 3. Body composition, ﬁtness, strength and gastro-oesophageal reﬂux outcomes at baseline and week-24 comparing participants in the
exercise group and control group.




n Mean (SD) Mean (SD) Mean (95%CI) % change Mean (95%CI) p-valuea
Waist circumference (cm)
Exercise group 17 105.3 (8.2) 100.2 (4.9) -5.1 (-7.1, -2.9) -4.8 -4.4 (-7.5,-1.4) < 0.01
Control group 15 104.8 (10.6) 104.2 (9.7) -0.6 (-2.9, 1.6) -0.6
Weight (kg)
Exercise group 17 94.7 (10.5) 92.3 (12.1) -2.5 (-4.1, -0.8) -2.6 -2.0 (-4.4,0.4) 0.10
Control group 15 92.4 (9.6) 91.5 (9.5) -0.5 (-2.2, 1.3) -0.5
Fat mass (kg)
Exercise group 17 22.0 (6.1) 19.9 (6.5) -2.0 (-4.2, 0.2) -9.2 -1.6 (-4.9,1.7) 0.32
Control group 15 21.6 (8.7) 21.4 (6.2) -0.3 (-2.7, 2.0) -1.5
Lean Mass (kg)
Exercise group 17 72.6 (10.3) 72.3 (10.4) -0.1 (-2.5, 2.3) -0.1 0.4 (-3.1,4.0) 0.80
Control group 15 70.9 (7.6) 70.1 (6.9) -0.5 (-3.1, 2.0) -0.7
VO2 peak (mL/min/kg)
Exercise group 15 26.1 (8.2) 32.2 (7.1) 5.5 (2.2, 8.7) 21.1 4.5 (-0.3,9.2) 0.06
Control group 13 26.8 (7.5) 27.9 (5.8) 1.0 (-2.4, 4.4) 3.7
Bench press (kg)
Exercise group 15 37.1 (14.3) 47.0 (13.9) 11.7 (7.1, 16.4) 31.5 9.7 (3.0,16.3) < 0.01
Control group 14 35.0 (13.3) 36.8 (14.1) 2.1 (-2.7, 6.8) 6.0
Leg Press (kg)
Exercise group 15 136.5 (35.2) 167.8 (35.7) 32.6 (17.8, 47.3) 23.9 11.7 (-9.5,33.0) 0.26
Control group 15 140.2 (46.6) 161.5 (48.1) 20.8 (5.6, 36.1) 14.8
Gastro-oesophageal reﬂuxb
Exercise group 17 10.8 (1.0) 11.4 (0.7) 0.5 (0.0, 1.0) 4.6 0.26 (-0.5,1.0) 0.46
Control group 15 10.8 (1.5) 11.2 (1.2) 0.2 (-0.3, 0.7) 1.9
a Change in exercise group versus change in control group, adjusted for baseline value (ANCOVA).
b Measured using Gastro-oesophageal reﬂux disease impact scale.
doi:10.1371/journal.pone.0117922.t003
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recurring challenge for intervention research in Barrett’s oesophagus. By analogy, a dietary and
weight loss trial targeting a very similar patient population in the US with biomarker endpoints
had a similar rate of recruitment as this study [12]. Due to the minimal adverse events reported,
future trials should consider using less strict eligibility criteria and/or recruiting across multiple
cities. Direct mailing of study information sheets to patients identified from hospital and re-
search databases, was the most effective recruitment strategy in this study. Use of a dedicated
clinical trials/research nurse to identify and recruit patients in clinics, rather than relying on
clinicians to provide study information to patients during routine appointments, would also as-
sist with recruitment [49]. Subsequent effectiveness-based trials which used different or more
flexible strategies for increasing exercise participation, may assist to increase the reach and rep-
resentativeness of those recruited into the trial.
The exercise protocol included one supervised and four unsupervised sessions (with free
gym membership provided). While adherence to the single supervised session was good (78%),
adherence to the four independent gym-based exercise sessions was moderate (56%). Previous
exercise trials for primary prevention of cancer have included 2–3 supervised sessions per week
with the unsupervised sessions primarily as home-based exercise [25]. A greater number of su-
pervised exercise sessions may have improved adherence to the exercise protocol in the current
study. Furthermore, almost a third of participants in the attention control group reported
exercising for more than one hour per week on at least five weeks over the study period; thus
the intervention effects observed on the primary outcomes may be underestimated. To mini-
mise contamination, stretching sessions were held at different times to the exercise group ses-
sions and attention control group participants were instructed to maintain their usual physical
activity levels. However contamination is common in exercise trials, where participants can
freely choose to engage in the ‘active treatment’, as opposed to placebo-controlled drug trials.
Contamination rates in control groups in other exercise trials have ranged from 12% to 52%
[50,51], which serve to under-estimate the treatment effect.
In this trial, a statistically significant reduction in waist circumference was observed after
24-weeks of exercise, compared to attention-control stretching. Visceral adiposity has recently
been shown to be a more important risk factor for oesophageal adenocarcinoma than measures
of overall obesity (such as BMI) [18–20]. The reduction in waist circumference following the
exercise intervention may therefore confer an important reduction in cancer risk for these men
with Barrett’s oesophagus. Findings from a large cohort study indicated a 16% (95% CI 1.04–
1.29) increased risk of oesophageal adenocarcinoma for every 5.0cm increase in waist circum-
ference [18]. Future trials should consider inclusion of more accurate measures of body com-
position, including body fat distribution [19].
No statistically significant effect on any of the primary outcomes was observed. While it is
possible that the exercise had no beneficial effect on these biomarkers, low power (inadequate
sample size) must also be considered, as 95% confidence intervals were wide. Leptin, in particu-
lar, for which a non-significant but clinically meaningful effect (>10% difference defined a pri-
ori) was observed in this sample (-3.0 [95% CI-6.6, 0.6] ng/mL; p = 0.09), may warrant further
investigation in larger studies, considering the substantial evidentiary support from the litera-
ture for the potential relevance of this biomarker. Leptin, a hormone secreted by adipocytes
and increased in the obese state, has been postulated in the development of oesophageal adeno-
carcinoma as well as other cancers [52,53]. In vitro, leptin has been shown to elicit mitogenic,
angiogenic and anti-apoptotic effects when administered to oesophageal adenocarcinoma cell
lines, enhancing cellular proliferation [54–57]. Recently, elevated leptin concentrations have
been associated with progression from Barrett’s oesophagus to oesophageal adenocarcinoma in
men independent of adiposity [24]. Similarly, increased leptin levels have been shown to be as-
sociated with increased risk of Barrett’s oesophagus in males, independent of adiposity [41,58].
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The reduction in leptin concentrations following the exercise intervention in the present study
(-21.2% in exercise group vs. +4.6% in control group) is therefore likely to be important in re-
ducing risk of oesophageal adenocarcinoma. Intervention trials in inactive, overweight adults
without Barrett’s oesophagus have also observed significant reductions in leptin following exer-
cise, with these reductions largely mediated by reductions in adiposity [26,59].
No significant intervention effect was observed for adiponectin, insulin resistance, or in-
flammatory markers (CRP, IL-6 and TNF-a) although the findings were inconclusive. Concen-
trations of CRP, HOMA and total adiponectin however significantly reduced within both
groups from baseline to week-24. While the stretching group was included to control for con-
tact between study groups, even this minimal-intensity program (one supervised stretching ses-
sion/week and four independent sessions/week; 45 mins/session) may have led to
improvements in some hormonal and inflammatory markers via a reduction in psychological
stress [60,61] or metabolic mechanisms [62]. More substantial reductions in adiposity may be
necessary to increase adiponectin [63] (a hormone which usually increases with decreasing adi-
posity [64] and reduce inflammatory markers such as IL-6 and TNF-a [65]. Results of exercise
interventions in populations without Barrett’s oesophagus have shown conflicting effects on
changes in adiponectin concentrations [64,66]. The reduction in adiponectin concentration ob-
served (despite modest weight loss) may be due to concomitant alterations in other hormones
and cytokines in response to exercise alone [64,67,68]. The magnitude of weight loss observed
in the EPOC trial is consistent with that observed in other exercise only interventions [69,70].
Interventions targeting both diet and exercise are necessary to achieve greater weight loss
[71,72], and may be more likely to result in beneficial changes in adipokines and inflammatory
markers [64].
The only other study to examine a lifestyle intervention in adults with Barrett’s oesophagus
to date focused on a dietary-only intervention (low fat, high fruits and vegetables) and weight
loss [12]. A between-group difference in weight of-4.0kg was observed at 18-months but no sig-
nificant effects on markers of cellular proliferation, re-epithelialization or Barrett segment
length were observed. Findings from the study by Kristal and colleagues [12] and our study,
suggest that greater weight loss may be necessary to substantially reduce risk of oesophageal
adenocarcinoma in men with Barrett’s oesophagus.
The primary limitation of the study is the small sample size and low statistical power, as pre-
viously noted. Additionally, the use of biomarkers associated with oesophageal adenocarcino-
ma risk as outcomes cannot determine whether a causal relationship exists between physical
activity and oesophageal cancer in men with Barrett’s oesophagus; such a trial would not be
feasible to conduct. Measuring associated biomarkers can however, provide important infor-
mation about the possible benefits and harms of physical activity interventions in individuals
with Barrett’s oesophagus, in addition to increasing the understanding of the underlying bio-
logic pathways potentially involved in exercise and cancer prevention. Furthermore, assess-
ment of unsupervised exercise sessions was based on self-reported exercise diaries. Objective
measurement of physical activity via accelerometers or other wearable devices that measure
both duration and intensity over longer periods, in future trials would assist in assessing adher-
ence to the intervention and monitoring cross-contamination. More frequent assessments of
actual dietary intake, for example with a daily food diary, would provide better assessment of
changes in dietary intake throughout the study period.
Conclusion
This small, exploratory trial provides novel evidence that a moderate-intensity aerobic and re-
sistance exercise intervention is feasible to deliver in overweight and inactive men with
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Barrett’s oesophagus and resulted in modest beneficial effects on waist circumference and lep-
tin concentrations, important risk factors for oesophageal adenocarcinoma. It is likely that
greater changes in adiposity, in particular reductions in visceral adiposity, may be required to
substantially reduce cancer risk in men with Barrett’s oesophagus. Future research should in-
vestigate a combined dietary and exercise intervention on these intermediate biomarkers in
this at risk and understudied population. Such evidence would inform recommendations
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